Regencell Bioscience HoldingRGC
13F holders, Q2 2024 (June 30)3holders
0new positions
0sold out
$3.36avg. 13F price*
At the end of Q2 2024, 3 institutions reported holding Regencell Bioscience Holding (RGC) in their 13F filings, unchanged from Q1 2024. 0 opened new positions and 0 sold out. The largest holders were UBS Group AG ($1K), BlackRock Inc. ($800) and Qube Research & Technologies Ltd ($44).
- Company
- Regencell Bioscience Holding
- CUSIP
- G7487R100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 1,088 shares sold, net −1,088 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| UBS Group AG | 0.00% | Reduce -77.7% | 312 | $1K |
| BlackRock Inc. | 0.00% | No change | 238 | $800 |
| Qube Research & Technologies Ltd | 0.00% | No change | 13 | $44 |
"% of holder's portfolio" is RGC's weight in each manager's 13F, not the share of Regencell Bioscience Holding the manager owns.